At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IBB iShares Biotechnology ETF
Trading 07-15 11:18:53 EDT
189.14
+0.47
+0.25%
High189.14Low186.84Vol231.99K
Open188.25D1 Closing188.67Amplitude1.22%
Mkt Cap9.23BTradable Cap9.23BTotal Shares48.80M
T/O43.66MT/O Rate0.48%Tradable Shares48.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021
Dow Jones  ·  32 minutes ago
Vertex Pharmaceuticals Currently Down Seven Consecutive Days, on Pace for Longest Losing Streak Since August 2021
Sector Update: Healthcare Stocks Decline Premarket Wednesday
MT Newswires Live  ·  21:15
Sector Update: Healthcare Stocks Decline Premarket Wednesday
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
TIPRANKS  ·  21:00
After Crinetics’ $10 Billion Deal, Could Entera Bio Be the Next Category-Defining Oral Peptide Story?
Ernexa Therapeutics announces new ERNA-101 preclinical data
TIPRANKS  ·  20:15
Ernexa Therapeutics announces new ERNA-101 preclinical data
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
GlobeNewswire  ·  19:30
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal
Simply Wall St.  ·  18:33
Crinetics Pharmaceuticals (CRNX) Looks Fully Valued As Vertex Agrees $85 Per Share Deal
African Markets - Factors to Watch on July 15
Reuters  ·  12:00
African Markets - Factors to Watch on July 15
Regeneron’s dupilumab granted orphan drug designation
TIPRANKS  ·  05:05
Regeneron’s dupilumab granted orphan drug designation
Celcuity announces FDA approval of Revtorpyk
TIPRANKS  ·  04:55
Celcuity announces FDA approval of Revtorpyk
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  04:34
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Sector Update: Healthcare Stocks Mixed Premarket Tuesday
MT Newswires Live  ·  07-14 21:15
Sector Update: Healthcare Stocks Mixed Premarket Tuesday
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Warsh Testimony
MT Newswires Live  ·  07-14 21:04
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of Warsh Testimony
Congo Begins Trial of Gilead's Experimental Antiviral for Ebola Bundibugyo
Reuters  ·  07-14 20:46
Congo Begins Trial of Gilead's Experimental Antiviral for Ebola Bundibugyo
Caris Life Sciences expands prostate cancer offering with PTEN IHC testing
TIPRANKS  ·  07-14 20:35
Caris Life Sciences expands prostate cancer offering with PTEN IHC testing
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong, Underperforms Competitors
Dow Jones  ·  07-14 16:33
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong, Underperforms Competitors
Nexalis Therapeutics Options Expire Unexercised, Streamlining Capital Structure
TIPRANKS  ·  07-14 13:27
Nexalis Therapeutics Options Expire Unexercised, Streamlining Capital Structure
Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights
TIPRANKS  ·  07-14 13:27
Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights
BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s
TIPRANKS  ·  07-14 06:08
BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s
Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment
TIPRANKS  ·  07-14 04:57
Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  07-14 04:35
Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Introduction

Company Name.
iShares Biotechnology ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Issue price:
--